These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 26347153)

  • 1. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
    van Werkhoven CH; Bonten MJ
    Future Microbiol; 2015; 10(9):1405-13. PubMed ID: 26347153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
    Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
    Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.
    van Werkhoven CH; Hollingsworth RC; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Sanders EA; Bonten MJ
    Vaccine; 2016 Jun; 34(28):3275-82. PubMed ID: 27171754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
    Isturiz R; Webber C
    Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
    Huijts SM; Coenjaerts FEJ; Bolkenbaas M; van Werkhoven CH; Grobbee DE; Bonten MJM;
    Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
    van Werkhoven CH; Bolkenbaas M; Huijts SM; Verheij TJM; Bonten MJM
    Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theory and strategy for Pneumococcal vaccines in the elderly.
    Namkoong H; Ishii M; Funatsu Y; Kimizuka Y; Yagi K; Asami T; Asakura T; Suzuki S; Kamo T; Fujiwara H; Tasaka S; Betsuyaku T; Hasegawa N
    Hum Vaccin Immunother; 2016; 12(2):336-43. PubMed ID: 26406267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal pneumonia prevention among adults: is the herd effect of pneumococcal conjugate vaccination in children as good a way as the active immunization of the elderly?
    Prato R; Fortunato F; Martinelli D
    Curr Med Res Opin; 2016; 32(3):543-5. PubMed ID: 26652736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
    Isturiz RE; Hall-Murray C; McLaughlin JM; Snow V; Schmoele-Thoma B; Webber C; Thompson A; Scott DA
    Expert Rev Vaccines; 2018 Jan; 17(1):45-55. PubMed ID: 29183235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
    Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.
    Esposito S; Principi N;
    Future Microbiol; 2015; 10(10):1599-607. PubMed ID: 26439470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
    van Werkhoven CH
    Hum Vaccin Immunother; 2017 May; 13(5):1177-1181. PubMed ID: 27937061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.
    Huijts SM; van Werkhoven CH; Bolkenbaas M; Grobbee DE; Bonten MJM
    Vaccine; 2017 Aug; 35(34):4444-4449. PubMed ID: 28410813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay.
    Pletz MW; Ewig S; Rohde G; Schuette H; Rupp J; Welte T; Suttorp N; Forstner C;
    Vaccine; 2016 Apr; 34(20):2342-8. PubMed ID: 27016653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
    Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
    Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
    Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
    N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
    Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
    Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.